Transperineal Laser Ablation Treatment (TPLA) for Prostate Cancer (PCa) Registry (TPLAforPCa)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05163197|
Recruitment Status : Recruiting
First Posted : December 20, 2021
Last Update Posted : December 20, 2021
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Rationale: Transperineal laser ablation (TPLA) treatment for prostate cancer (PCa) is a minimal invasive focal therapy technique studied worldwide to determine its efficacy. In pilot studies it has shown to be a safe and feasible technique and it has potential to preserve continence and potency over current standard radical therapies. However, (long-term) treatment outcomes of TPLA for PCa remain largely unknown. The aim of this international retrospective registry is to collect and combine data on patients treated TPLA for PCa in order to provide data on safety, feasibility, functional and oncological outcomes.
Objective: To assess safety and feasibility of TPLA for PCa, to assess functional and oncological outcomes of TPLA for PCa and to determine baseline patient characteristics in a multicentre cohort.
Study design: This is an international, retrospective observational registry in which data is recorded of patients who have been treated with TPLA for PCa.
Study population: Male patients treated with TPLA for PCa. Main study parameters/endpoints: The primary endpoint of this registry is oncological outcomes of TPLA for PCa. Secondary endpoints are safety, feasibility and functional outcomes of TPLA for PCa.
|Condition or disease||Intervention/treatment|
|Prostate Cancer||Procedure: Transperineal Laser Ablation of Prostate Cancer|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||200 participants|
|Target Follow-Up Duration:||5 Years|
|Official Title:||Transperineal Laser Ablation Treatment for Prostate Cancer Registry: a Retrospective and Multicenter Evaluation|
|Actual Study Start Date :||October 1, 2021|
|Estimated Primary Completion Date :||October 1, 2026|
|Estimated Study Completion Date :||October 1, 2027|
- Procedure: Transperineal Laser Ablation of Prostate Cancer
Minimal invasive transperineal laser ablation treatment for prostate cancerOther Names:
- Soractelite treatment
- Echolaser X4
- Oncological control [ Time Frame: 12 months ]Oncological control is defined as: a PSA <=2.0ng/mL than initial PSA and/or no residual tumor or other lesion suspicious for prostate cancer on magnetic resonance imaging and/or no gleason score upgrading on re-biopsy and/or no clinical up-staging of prostate cancer T-stage
- Continence rate [ Time Frame: 12 months ]Continence is assessed by usage of number of pads per day, and 0-1 pad per day usage is defined as continent.
- Potency rate [ Time Frame: 12 months ]Potency is defined as erectile function sufficient for sexual intercourse, with or without medical aid
- Urinary flow [ Time Frame: 12 months ]Urinary flow is assessed by peak urinary flow (mL/s) and residual urine (mL). The higher the peak urinary flow and the lower the residual urine, the better the urinary flow.
- PROM regarding voiding [ Time Frame: 12 months ]International Prostate Symptom Score (IPSS) is used to determine functional outcome regarding voiding. IPSS is on a score of 0 to 35, and the higher the score the worse the outcome.
- PROM regarding erectile function [ Time Frame: 12 months ]International Index of Erectile Function (IIEF-5) is used to determine erectile function based on a validated questionnaire. IIEF-5 is on a scale of 5 to 25, and the higher the score the better the outcome.
- Safety of TPLA for PCa [ Time Frame: Up to 12 weeks ]Safety is defined as 10% or less CTCAE (version 5) grade 3 and no CTCAE grade 4 or 5
- Feasibility of TPLA for PCa [ Time Frame: Up to 4 weeks ]Feasibility is assessed by amount of machine failures perioperatively of TPLA and hospital duration (hours) directly after TPLA.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
- Male, histological-confirmed disease of localized prostate cancer, TPLA treatment for PCa is performed
- Age < 18 years
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05163197
|Contact: L. A. van Riel, MD||+31 6 50 06 30 email@example.com|
|Contact: J. R. Oddens, MD, PhD||+31 6 50 06 30 firstname.lastname@example.org|
|Amsterdam University Medical Centers||Recruiting|
|Contact: L. A. van Riel, MD +31 6 50 06 30 94 email@example.com|
|Principal Investigator:||J. R. Oddens, MD, PhD||Principal Investigator|
|Responsible Party:||Prof.dr. H.P. Beerlage, Professor, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|
|Other Study ID Numbers:||
|First Posted:||December 20, 2021 Key Record Dates|
|Last Update Posted:||December 20, 2021|
|Last Verified:||December 2021|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Genital Neoplasms, Male
Neoplasms by Site